Compare Vaxcyte Inc. Common Stock (PCVX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Plby Group Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.63B), while Plby Group Inc trades at $0.97 (market cap $118.61M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 89.6× Plby Group Inc's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Plby Group Inc for 24 Days on average.
| PCVX | PLBY | |
|---|---|---|
Market Cap | $10.63B | $118.61M |
Volume | 1,525,205 | 1,149,362 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.82 | $2.71 |
52-Week Low | $40.32 | $0.98 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $9.26B | $264.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PLBY Group trades at $1.02, up 2.7% today, amid a bearish technical outlook with mixed fundamentals. The company shows improving financial trends with revenue stabilizing around $120M and narrowing losses, but remains unprofitable with negative shareholder equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
While analyst consensus is strongly bullish (75% buy ratings), significant risks persist including high debt levels, negative equity, and inconsistent earnings performance. The stock's valuation appears stretched with a P/E of 51, requiring sustained operational improvement to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
